The University Of Texas MD Anderson Cancer Center

Photon and proton beam radiation therapies conferred similar outcomes for men with localized prostate cancer, according to results of a randomized phase 3 trial.

Immunotherapy before and after surgery significantly improved EFS compared with neoadjuvant immunotherapy only for patients with resectable non-small cell lung cancer, according to a comparison of results from two randomized phase 3 trials.

The addition of comprehensive metastasis-directed radiation therapy to chemotherapy improved outcomes for patients with oligometastatic pancreatic ductal adenocarcinoma, according to results of a randomized phase 2 basket trial.

Spouses of people with cancer exhibited significantly higher risk for attempted suicide and suicide death than those whose spouses had not been diagnosed with cancer, according to a nationwide cohort study in Denmark.

American Society for Radiation Oncology selected 48 members to receive ASTRO fellow designation.

Obecabtagene autoleucel conferred durable benefit to certain patients with relapsed or refractory B-cell acute lymphoblastic leukemia, according to results of the phase 1B/phase 2 FLEIX study presented at ASCO Annual Meeting.

The University of Texas MD Anderson Cancer Center has retained its distinction as the No. 1 cancer hospital in the country.

A higher proportion of women faculty members in academic radiation oncology treated cancer types associated with the female gender compared with men faculty, according to study results.

CHICAGO — Durvalumab conferred significant survival benefits in patients with limited-stage small-cell lung cancer following standard-of-care treatment in a randomized phase 3 trial, according to findings presented at ASCO Annual Meeting.

Richard Gorlick, MD, received this year’s ASCO Pediatric Oncology Award, which recognizes an individual who made outstanding contributions to the field.